share_log

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax製藥 | CORRESP:信函
美股SEC公告 ·  05/03 12:35

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.
Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.
Virpax藥品公司已正式撤回其在2024年4月18日首次提交的S-1表格的註冊聲明加速生效日期的請求。該公司此前曾於2024年5月2日提交了一份請求,希望讓註冊聲明在東部時間2024年5月2日下午5點之前生效,以加快進程。然而,在2024年5月3日致美國證券交易委員會的一份信函中,Virpax的首席執行官Gerald Bruce表示該公司不再追求加速生效日期,並撤回了請求。該信函是地址給SEC的公司融資部門的Daniel Crawford。
Virpax藥品公司已正式撤回其在2024年4月18日首次提交的S-1表格的註冊聲明加速生效日期的請求。該公司此前曾於2024年5月2日提交了一份請求,希望讓註冊聲明在東部時間2024年5月2日下午5點之前生效,以加快進程。然而,在2024年5月3日致美國證券交易委員會的一份信函中,Virpax的首席執行官Gerald Bruce表示該公司不再追求加速生效日期,並撤回了請求。該信函是地址給SEC的公司融資部門的Daniel Crawford。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息